CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

PHR160 SprayWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation

Correlated Drug Terms (4)

Name (Synonyms) Correlation
drug2163 Placebo solution Wiki 1.00
drug1744 Methylprednisolone Sodium Succinate Wiki 0.71
drug2730 Standard treatment Wiki 0.41
drug2122 Placebo Wiki 0.05

Correlated MeSH Terms (4)

Name (Synonyms) Correlation
D013577 Syndrome NIH 0.10
D011014 Pneumonia NIH 0.06
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.06

There is one clinical trial.

Clinical Trials

1 Safety and Efficacy of PHR 160 Spray on the Outcomes of Patients With COVID-19 a Multi-center Randomized Blinding Clinical Trial Study

This study is a multi-center randomized, controlled, and blinded clinical trial study that will be performed in four medical-educational centers. In this study, the samples will be selected from among patients with SARS-CoV-2 as easy access and based on entry criteria and will be randomly divided into two groups, including a control group and an intervention group. The study will be conducted in four medical centers. From each center, 56 definitive Corona patients will be selected, who will be randomly divided into two groups of 28, for a total of 224 patients will enter the study. In the intervention group, in addition to receiving the test spray, Patients will also receive standard treatment

NCT04463420 COVID-19 Drug: PHR160 Spray Drug: Placebo Drug: Standard treatment

Primary Outcomes

Description: shortness of breath measured by Visual analog scale (VAS) dyspnea score. The minimum score is zero means shortness of breath and the highest score is 10 means the maximum intensity of shortness of breath.

Measure: Dyspnea

Time: up to 14 days

Secondary Outcomes

Description: The length of time the patient is hospitalized after the diagnosis of COVID-19

Measure: long of hospitalization

Time: up to 28 days

Description: CT scans help determine how much the lungs are affected by COVID-19.

Measure: Radiological Treatment Response

Time: up to 14 days

Description: In-hospital mortality

Measure: Mortality

Time: Up to 28 days

Description: There will be known allergic reactions to the drugs.

Measure: Allergic drug

Time: up to 14 days

Description: Normal blood cell count and CRP count (normal laboratory range)

Measure: Laboratory Treatment Response

Time: up to 14 days

Description: Using an oximeter pulse, the amount of oxygen saturation is measured. If the patient is receiving oxygen, first cut off the oxygen for 5 minutes and then measure. If the oxygen drops below 90 degrees, oxygen therapy will be re-established immediately.

Measure: O2 saturation without supplemental oxygen

Time: up to 14 days

Description: Complications in both groups should be evaluated and evaluated during treatment. protective response that serves to clear the trachea, bronchi, and/or lungs of irritants and secretions that measured by Physical examination.

Measure: drug reactions Adverse

Time: Up to 14 days

No related HPO nodes (Using clinical trials)